Lib Therapeutics INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersCincinnati, OH
US patents3
SAM.gov UEIGXLUKVAN7WC8
CAGE code199H7
Incorporated inDE
- developing lerodalcibep
- PCSK9 inhibitor
- monthly subcutaneous dose
- therapies
- cardiovascular disease
- treatment
- high cholesterol
- familial hypercholesterolemia
- treatments
- limitations
- statins
Named on the company’s own website, read JUL 29, 2026
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
3 US patents granted 2020–2025, 2 of them in the five years to SEP 2025.
Pharmaceuticals 3
- Compositions comprising PCSK9-binding molecules and methods of useUS 12,410,236 · granted SEP 9, 2025
- Compositions comprising PCSK9-binding molecules and methods of useUS 11,692,021 · granted JUL 4, 2023
- Compositions comprising PCSK9-binding molecules and methods of useUS 10,738,102 · granted AUG 11, 2020
Granted to LIB Therapeutics, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Lib Therapeutics INC | Cincinnati | OH | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.